These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 34990047

  • 41. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 42. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T.
    Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
    [Abstract] [Full Text] [Related]

  • 43. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C, Ferreira AN, de Paula M, Viana L, Cristelli M, Medina Pestana J, Tedesco-Silva H.
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [Abstract] [Full Text] [Related]

  • 44. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [Abstract] [Full Text] [Related]

  • 45. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D.
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [Abstract] [Full Text] [Related]

  • 46. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, González E, Moreso FJ, Gómez-Alamillo C, Mendiluce A, Luna-Huerta E, Aguado JM, OPERA Study Group.
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [Abstract] [Full Text] [Related]

  • 47. Evaluation of T-Cell Immune Status of Reduced-Dose Cyclosporine and Everolimus Combination Therapy in Kidney Transplant Patients.
    Tanaka A, Ide K, Tanaka Y, Sasaki Y, Doskali M, Tahara H, Ohira M, Ohdan H.
    Transplant Proc; 2023 May; 55(4):797-802. PubMed ID: 37032288
    [Abstract] [Full Text] [Related]

  • 48. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.
    Fernández-García OA, García-Juárez I, Belaunzarán-Zamudio PF, Vilatoba M, Wisniowski-Yáñez A, Salomón-Ávila J, Bobadilla-Del-Valle M, Sifuentes-Osornio J, Cuellar-Rodríguez JM.
    BMC Infect Dis; 2022 Feb 14; 22(1):155. PubMed ID: 35164684
    [Abstract] [Full Text] [Related]

  • 49. Cytomegalovirus transmission in mismatched solid organ transplant recipients: Are factors other than anti-viral prophylaxis at play?
    Hernandez C, Mabilangan C, Burton C, Doucette K, Preiksaitis J.
    Am J Transplant; 2021 Dec 14; 21(12):3958-3970. PubMed ID: 34174153
    [Abstract] [Full Text] [Related]

  • 50. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P, Felipe C, Ferreira A, Cristelli M, Viana L, Mansur J, Basso G, Hannun P, Aguiar W, Tedesco Silva H, Medina-Pestana J.
    Transplantation; 2017 Apr 14; 101(4):844-850. PubMed ID: 27490418
    [Abstract] [Full Text] [Related]

  • 51. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct 14; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

  • 52. Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.
    Melancon K, Mulgaonkar SP, Delcoro C, Wiland A, McCague K, Shihab FS.
    Transplantation; 2013 Dec 27; 96(12):1073-81. PubMed ID: 24345868
    [Abstract] [Full Text] [Related]

  • 53. Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients.
    Kumar L, Dasgupta S, Murray-Krezan C, Singh N, Rakita RM, Fisher CE, Limaye AP.
    Clin Infect Dis; 2024 Mar 20; 78(3):719-722. PubMed ID: 37862162
    [Abstract] [Full Text] [Related]

  • 54. Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A Prospective, Randomized Trial.
    Viana LA, Cristelli MP, Basso G, Santos DW, Dantas MTC, Dreige YC, Requião Moura LR, Nakamura MR, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2023 Aug 01; 107(8):1835-1845. PubMed ID: 37046380
    [Abstract] [Full Text] [Related]

  • 55. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).
    Manzia TM, Carmellini M, Todeschini P, Secchi A, Sandrini S, Minetti E, Furian L, Spagnoletti G, Pisani F, Piredda GB, Cappelli G, Tisone G.
    Transplantation; 2020 Feb 01; 104(2):374-386. PubMed ID: 31335776
    [Abstract] [Full Text] [Related]

  • 56. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec 01; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 57. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.
    Transpl Infect Dis; 2019 Dec 01; 21(6):e13166. PubMed ID: 31487755
    [Abstract] [Full Text] [Related]

  • 58. Reliability of QuantiFERON®-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
    Sermet K, Goeminne C, Hantz S, Assaf A, Faure E, Lazrek M, Faure K, Alain S, Vuotto F.
    Clin Transplant; 2023 Dec 01; 37(12):e15109. PubMed ID: 37641575
    [Abstract] [Full Text] [Related]

  • 59. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N, Mengelle C, Esposito L, Guitard J, Mehrenberger M, Lavayssière L, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L.
    J Med Virol; 2008 Jun 01; 80(6):1012-7. PubMed ID: 18428146
    [Abstract] [Full Text] [Related]

  • 60. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F, Rueda B, Lizasoain M, Juan RS, Folgueira D, Andrés A, Morales JM, Jiménez C, Meneu JC, Aguado JM.
    Transpl Infect Dis; 2009 Oct 01; 11(5):400-4. PubMed ID: 19570139
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.